From November 30 to December 1, 2024, the 2024 China BioMed Innovation and Investment Conference (CBIIC) hosted the first-ever Non-listed Company Roadshow in Guangzhou. The Roadshow featured 29 outstanding projects, which were presented to investors, partners, and industry experts over the two days of the event, showcasing cutting-edge achievements and tremendous potential across various therapeutic fields.

The Roadshow Session meticulously organized three major events aimed at providing a global platform for pharmaceutical innovation projects, fostering collaboration within the industry. Three industry leaders were invited to host the session: Mr. Du Xiangyang, Deputy Director and Chief Healthcare Analyst of Southwest Securities Equity Research Department, Mr. Yang Yehui, Executive Director of Hua Ying Securities and former head of the Guolian Securities Research Institute, and Mr. He Fengzhi, General Manager of BK Healthcare Capital. Their leadership contributed to a series of intellectual exchanges and thought-provoking discussions for the attendees. 

Opening Report Leading the New Horizon of the Industry

In this Roadshow, Ms. Lena Gong, General Manager and Chairwoman of Zhuhai Hengqin Haomai Technology Co., Ltd., delivered the keynote speech titled Big Data Enabling Project R&D and Trading: from “Foreseeing the Future” to “Meeting the Future”. The report delved into key issues in the pharmaceutical industry related to asset transactions, product initiation, and R&D strategies, emphasizing the use of big data analytics and comprehensive strategies to promote product internationalization and attract buyer attention.

Mr. Wang Xiaokun, Co-Managing Director of CCBI Capital Limited, provided an in-depth analysis of “Key Topics in Healthcare Industry of Hong Kong Capital Market”

and “Key Topics in Biopharmaceutical Companies’ IPOs in Hong Kong.”His presentation focused on the latest developments in the Hong Kong capital market and the healthcare sector, including recent market trends, performance of the healthcare sector, advantages of Hong Kong listings, the status of the 18A listing board, and details regarding listings on the main board. His insights offered new perspectives and valuable industry intelligence to the attendees.

Highlights of Roadshow Projects

Wuhan Yicheng Biotechnology is committed to developing innovative drugs for the treatment of inflammation and autoimmune diseases. Its anti-inflammatory drug, Epivotide, is the world’s first specific inhibitor targeting the p55PIK subunit of the PI3K regulatory family. This drug does not produce toxic side effects in humans and can be used to treat inflammation and autoimmune diseases. With global patent protection, Epivotide offers significant economic potential due to its superior efficacy compared to existing anti-inflammatory drugs, its large patient base, and its ability to be freely priced.

VISEN Pharmaceuticals is an innovative biopharmaceutical company focused on endocrine-related treatments. Its leading product, Lonapegsomatropin, is the first long-acting growth hormone approved for use in the U.S. and Europe to treat children with growth hormone deficiency. Administered once a week, it helps children with growth hormone deficiency achieve or approach normal height. Global and Chinese Phase 3 clinical trials have confirmed that Lonapegsomatropin is the only long-acting growth hormone superior to daily growth hormone formulations. The Biologics License Application (BLA) for its use in treating pediatric growth hormone deficiency was formally accepted by China’s National Medical Products Administration (NMPA) in 2024.

NeuExcell Therapeutics founded by Professor Chen Gong during his tenure at Pennsylvania State University in the U.S., holds over 200 patent applications and has received 57 international patent grants. Its core technology is in-situ Neuroregenerative Gene Therapy, which directly converts abundant dividing astrocytes in the brain into functional neurons. This platform technology is suitable for the treatment of major brain diseases, including stroke, Alzheimer’s disease, glioma, Parkinso’s disease, Huntington’s disease, traumatic brain injury, retinal diseases, spinal cord injury, and amyotrophic lateral sclerosis (ALS). In March 2024, NeuExcell Therapeutics successfully administered the first patient dose of its AAV-NeuroD1 gene therapy product NXL-004, marking the world’s first clinical use of AAV-NeuroD1 gene therapy and the beginning of clinical research for this novel gene therapy.

Lupeng Pharmaceuticals’ core project, Rocbrutinib, is a self-developed small molecule Bruton’ tyrosine kinase inhibitor (BTKi) with global intellectual property rights, including in China. Beyond autoimmune diseases, Rocbrutinib is undergoing clinical trials for various types of relapsed/refractory B-cell lymphomas, including relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone Lymphoma (MZL), and Diffuse Large B-cell Lymphoma (DLBCL). Rocbrutinib has demonstrated particularly outstanding efficacy in relapsed/refractory non-GCB DLBCL compared to other therapies and was included in the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) list of breakthrough therapies in May 2024, making it the first BTKi to be recognized as a breakthrough therapy for DLBCL in China.

Binhui Biopharmaceutical initially focused on oncolytic virus drug development and has since established technology platforms in nucleic acid, protein, and cell therapies. Its core project, oncolytic virus OH2, is the first Type II Herpes Simplex Virus (HSV) oncolytic virus drug to enter clinical trials globally. The drug has received breakthrough therapy certification from the CDE, orphan drug status in the U.S., and fast-track status, completing preclinical and Phase I/II studies and advancing to Phase III clinical trials. Since its launch in 2018, the company has raised over 1 billion CNY.

Overseas Pharmaceuticals is an international company focused on innovative modified drugs, driven by a platform-based approach to meet unmet clinical needs. It specializes in the field of solid oral controlled-release formulations and has independently developed a series of innovative controlled-release platform technologies, such as Dual-trol, Dual-lease, Bi-lock, and Mech-trol. Several of these technologies have been granted patents in China, the U.S., Europe, and Japan, demonstrating its global market reach. These technologies are being applied to the development of controlled-release new drugs for various indications, building technical barriers and entry thresholds. 

At the Non-listed Company Roadshow, we witnessed sparks of pharmaceutical innovation and felt the strong anticipation of investors for the future. After nine successful years, the Roadshow has always been closely aligned with the pulse of pharmaceutical innovation and investment, working hand in hand with industry peers and advancing steadily. We look forward to the next gathering, where we will continue to discuss growth and development!